CanSino’s COVID-19 immunization competitor affirmed for military usage in China Kumar Jeetendra | June 29, 2020 China’s army has obtained the greenlight to utilize a COVID-19 vaccine candidate developed by its research component and CanSino Biologics (6185. HK) after clinical trials demonstrated that it was secure and marginally efficient, the business said on Monday. The Ad5-nCoV is just one of those eight vaccine candidates being developed by Chinese businesses and researchers …
